Health officials in New York are investigating vitamin E's connection to a string of vaping illnesses in the state; civil rights groups are suing the Trump administration over its decision to deport immigrants with life-threatening illnesses; an oncologist from MD Anderson Cancer Center met with President Trump about a potential nomination for FDA commissioner.
New York health officials are investigating the role of vitamin E acetate in a string of illnesses related to vaping, reported The New York Times. According to the state's Department of Health, there were “very high levels” of the compound identified in 13 samples from 8 of 34 patients in the state who have gotten sick. However, the case is not closed on what’s causing these illnesses, particularly since the compound hasn’t been confirmed as a factor in the majority of the cases. A spokesman for the FDA said that more information is needed to better understand if there’s a link between any specific substances and the illnesses.
Days after the Trump administration announced that it would reconsider its decision to deport immigrants with life-threatening illnesses, civil rights groups are suing the administration over the decision. The American Civil Liberties Union of Massachusetts and Lawyers for Civil Rights filed a lawsuit in Boston federal court challenging the decision to end the deferred action program as of August 7, according to The Associated Press. The groups argue that the decision was made without the advance public notice and justification required by law before changing a significant federal government regulation.
With the Trump administration looking to nail down a permanent FDA commissioner by November 1, STAT News has reported that Texas oncologist Stephen Hahn, MD, FASTRO, chief medical executive at MD Anderson Cancer Center, met with the president on Wednesday about a possible nomination. Unlike many past commissioners, Hahn has no Washington experience. Acting FDA Commissioner Ned Sharpless, MD, is also in the running, according to experts. Four former FDA commissioners have come out in support of Sharpless.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More